Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2010 1
2011 1
2012 1
2013 3
2014 3
2016 3
2017 1
2018 3
2019 4
2020 5
2021 6
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Cancer predisposition and germline CTNNA1 variants.
Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, Hüneburg R, Aretz S, Colas C, Oliveira C. Lobo S, et al. Among authors: boussemart l. Eur J Med Genet. 2021 Oct;64(10):104316. doi: 10.1016/j.ejmg.2021.104316. Epub 2021 Aug 21. Eur J Med Genet. 2021. PMID: 34425242
Vemurafenib and radiosensitization.
Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C. Boussemart L, et al. JAMA Dermatol. 2013 Jul;149(7):855-7. doi: 10.1001/jamadermatol.2013.4200. JAMA Dermatol. 2013. PMID: 23699661
First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants.
Coudert M, Drouet Y, Delhomelle H, Svrcek M, Benusiglio PR, Coulet F, Clark DF, Katona BW, van Hest LP, van der Kolk LE, Cats A, van Dieren JM, Nehoray B, Slavin T, Spier I, Hüneburg R, Lobo S, Oliveira C, Boussemart L, Masson L, Chiesa J, Schwartz M, Buecher B, Golmard L, Bouvier AM, Bonadona V, Stoppa-Lyonnet D, Lasset C, Colas C. Coudert M, et al. Among authors: boussemart l. J Med Genet. 2022 Dec;59(12):1189-1195. doi: 10.1136/jmg-2022-108740. Epub 2022 Aug 29. J Med Genet. 2022. PMID: 36038258
Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
Sfecci A, Dupuy A, Dinulescu M, Droitcourt C, Adamski H, Hadj-Rabia S, Odent S, Galibert MD, Boussemart L. Sfecci A, et al. Among authors: boussemart l. J Invest Dermatol. 2017 Apr;137(4):805-809. doi: 10.1016/j.jid.2016.12.012. J Invest Dermatol. 2017. PMID: 28340684 Free article. Review.
Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F. Nardin C, et al. Among authors: boussemart l. Cancers (Basel). 2023 Jul 10;15(14):3564. doi: 10.3390/cancers15143564. Cancers (Basel). 2023. PMID: 37509227 Free PMC article.
Metastatic melanoma: New paradigms of treatment and new toxicities.
Robert C, Mateus C, Routier E, Thomas M, Boussemart L, Eggermont AM. Robert C, et al. Among authors: boussemart l. EJC Suppl. 2013 Sep;11(2):278-80. doi: 10.1016/j.ejcsup.2013.07.046. EJC Suppl. 2013. PMID: 26217144 Free PMC article. Review. No abstract available.
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017.
Poizeau F, Kerbrat S, Happe A, Rault C, Drezen E, Balusson F, Tuppin P, Guillot B, Thuret A, Boussemart L, Dinulescu M, Pracht M, Lesimple T, Droitcourt C, Oger E, Dupuy A. Poizeau F, et al. Among authors: boussemart l. J Invest Dermatol. 2021 Apr;141(4):830-839.e3. doi: 10.1016/j.jid.2020.07.038. Epub 2020 Oct 10. J Invest Dermatol. 2021. PMID: 33049268 Free article.
Melanoma tumour vasculature heterogeneity: from mice models to human.
Pautu V, Mellinger A, Resnier P, Lepeltier E, Martin L, Boussemart L, Letournel F, Passirani C, Clere N. Pautu V, et al. Among authors: boussemart l. J Cancer Res Clin Oncol. 2019 Mar;145(3):589-597. doi: 10.1007/s00432-018-2809-z. Epub 2018 Dec 13. J Cancer Res Clin Oncol. 2019. PMID: 30547320
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, Bachelot L, Perrot A, Soshilov A, Rogiers A, Rambow F, Dumontet E, Tarte K, Bessede A, Guillemin GJ, Marine JC, Denison MS, Gilot D, Galibert MD. Corre S, et al. Among authors: boussemart l. Nat Commun. 2018 Nov 14;9(1):4775. doi: 10.1038/s41467-018-06951-2. Nat Commun. 2018. PMID: 30429474 Free PMC article.
33 results